NCT04009668 2024-10-30
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
University of Michigan
Phase 2 Completed
Clinical Trials
14 trialsNCT03180957 2024-06-28
RIDD
University of Oxford
Phase 2 Completed
NCT04255134 2023-05-18
BIORA-PAIN
St George's, University of London
Phase 4 Completed
NCT04798287 2022-06-22
STAR-RA-Cancer
Brigham and Women's Hospital
Completed
NCT02492217 2020-11-03
Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients
Universidade Nova de Lisboa
Phase 4 Completed
NCT01060098 2020-01-18
T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Imperial College London
Completed
NCT02778789 2019-09-26
Re-Bone
University of Erlangen-Nürnberg Medical School
Completed
NCT02437253 2017-09-15
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase 1/2 Completed
NCT00932113 2017-08-31
MOA
Tufts Medical Center
Phase 4 Completed
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT02376478 2015-03-03
On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection
Medical University of Vienna
Completed
NCT00597623 2012-07-26
DORA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT00497614 2008-12-05
PETRA
University Hospital, Tours
Phase NA Completed
NCT00696059 2008-06-12
HURRAH
Hvidovre University Hospital
Phase 4 Completed